Leuprolide Acetate Market Size

Leuprolide Acetate Market size was valued at USD 2.3 billion in 2024 and is likely to cross USD 5.41 billion by 2037, registering more than 6.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of chip-on-board LED is estimated at USD 2.43 billion. The reason behind the growth is impelled by the growing cases of cancer across the globe. Cancer is currently the third biggest cause of mortality which is majorly caused owing to the combined effects of genetic differences, environmental variables, and dietary decisions.

Advanced cancer patients may use leuprolide acetate as a palliative treatment since it is a well-known luteinizing hormone-releasing hormone (LHRH) agonist in prostate cancer. To grow and spread, the majority of prostate cancer forms require the hormone testosterone. According to estimates, in 2040, there will be more than 28 million new instances of cancer worldwide.

The growing prevalence of uterus fibroids are believed to fuel the leuprolide acetate market . For instance, in women of reproductive age, fibroids are the most prevalent type of pelvic tumor, and by the time they are 50 years old, more than 50% of women have fibroids. 

Leuprolide acetate is the most popular drug for treating uterine fibroids in women since it has been approved for reducing the size of fibroids.